| Similar Articles |
|---|
 |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies.   |
The Motley Fool
November 28, 2011
Brian Orelli |
Breaking Down a Biotech Press Release Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia. That sure is a mouthful. Let's see if we can break it down. |
The Motley Fool
July 29, 2011
Brian Orelli |
2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch. |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
September 27, 2011
Brian Orelli |
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. |
The Motley Fool
March 9, 2011
Brian Orelli |
Slicing and Dicing Your Way through Drug Development The drug developer announces that it licensed the Japanese rights to perifosine, its lead cancer drug, to Yakult Honsha. |
The Motley Fool
August 11, 2011
Sean Williams |
Aeterna Zentaris: Out of Sight, Out of Mind Perifosine, the company's lead cancer drug, hits key milestones. |
The Motley Fool
November 11, 2011
Sean Williams |
Aeterna Zentaris Surprises Again A quarterly profit shocks analysts and me alike. |
The Motley Fool
January 6, 2012
Brian Orelli |
Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate. |
The Motley Fool
January 18, 2012
Brian Orelli |
2 High-Flying Biotechs Face a New Hurdle The next number-one concern for Aeterna Zentaris' and Keryx's investors should be whether the drug passes its clinical trial. |
The Motley Fool
May 19, 2011
Sean Williams |
Aeterna Zentaris Continues to Deliver Positive Results The most important aspect of Aeterna Zentaris' quarterly filing is its partnership with Yakult Honsha in Japan. |
The Motley Fool
August 15, 2011
Jim Royal |
6 Wild Bets on Biotech Riches The most interesting biotech tickers. |
The Motley Fool
January 2, 2012
Sean Williams |
2012 Preview: Aeterna Zentaris Let's look ahead and see what will be driving Aeterna's stock price in 2012. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012. |
The Motley Fool
May 24, 2007
Mike Havrilla |
A New Era at AEterna A strong balance sheet and a pair of promising products underlie optimism for the biopharmaceutical's future prospects. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
December 23, 2011
Brian Orelli |
Geron's Hurry-Up-and-Wait Strategy Clinical trials started, now the waiting begins. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
The Motley Fool
November 23, 2011
Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool
November 9, 2011
Sean Williams |
3 Stocks to Get on Your Watchlist It's Watchlist Wednesday, and here's what's on my radar. |
The Motley Fool
January 18, 2012
Sean Williams |
3 Stocks Under $3 That Could Double in 2012 What these stocks lack in share price they make up for in potential. |
BusinessWeek
August 16, 2004
Gene G. Marcial |
Profits Loom For AEterna Zentaris The little-known Canadian biopharma has an array of cancer products that could push it to profitability after years of losses. The stock, now at $4.15, could reach $12 in a year. |
The Motley Fool
November 11, 2011
David Williamson |
Roundtable: 5 Must-Watch Stocks Highlighting companies experts are watching around the office. |
The Motley Fool
December 6, 2011
Rick Aristotle Munarriz |
2013 Is Closer Than You Think Some prolific stocks are cheaper than you think. |
